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Abstract
Background: The endomyocardial biopsy has proven to be an integral diagnostic tool for surveillance of cardiac allograft
rejection and identification of myocardial diseases. Nevertheless, this invasive procedure is not risk-free. This study focuses
on the risk of complications and diagnostic performance of right ventricular endomyocardial biopsy (EMB).
Methods: In this single-center retrospective study, we analyzed 315 EMB procedures performed between July 2008 and
May 2015 in 73 patients. All EMBs were made via the right femoral vein approach under fluoroscopic control to evaluate
suspected myocarditis, unclear heart failure, unexplained cardiomyopathy, assumed infiltrative and storage disease or as a
part of routine allograft rejection monitoring and clinically suspected rejection diagnosis after heart transplantation (HTx).
Obtained specimens were diagnosed histopathologically by one experienced pathologist. All patients underwent a
12-lead electrocardiogram (ECG), ECG monitoring, transthoracic echocardiography before and after EMB to obtain a
detailed assessment of the incidence of heart rhythm disorders, pericardial effusions or worsening valve insufficiency.
Complications resulting from the procedure were classified as major or minor according to the risk of death.
Results: Among all the 315 biopsies, 86.67% were performed in 32 patients after HTx, 3.81% in patients with
myocarditis, 2.54% in patients with dilated cardiomyopathy and 1.9% in patients with amyloidosis. The overall
complications rate was 1.9% (6 of 315 procedures). Major complications included perforation with pericardial
tamponade requiring surgical intervention (0.64%, 2 of 315 procedures). Minor complications included: pericardial
effusion (0.32%, 1 of 315 procedures), local hematoma (0.64%, 2 of 315 procedures) and right coronary artery-right
ventricle fistula in HTx recipient (0.32%, 1 of 315 procedures).
Conclusions: EMB is a safe procedure with low risk of serious complications and high effectiveness for the evaluation
of unexplained left ventricle dysfunction and monitoring allograft rejection after HTx.
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Background
The endomyocardial biopsy (EMB) constitutes an estab-
lished tool for surveillance of cardiac allograft rejection
and identification of myocardial diseases [1]. EMB plays
a pivotal role in diagnosis of myocarditis, infiltrative or
storage myocardial disorders and monitoring of heart
transplant rejection. EMB is also indicated in detecting of
cardiac tumors, cardiac toxicity as well as ventricular
arrhythmias [2]. In recent years, the utility and accuracy
of EMB is increasingly growing due to application of new
research tools including immunohistochemistry and
molecular biology techniques in identification of cardiac
diseases [3, 4]. EMB is most commonly performed
through the femoral or jugular vein access under the guid-
ance of fluoroscopy. The appropriate number samples
(usually 5–10) are generally obtained from interventricular
septum (IVS) [5]. However, samples may also be collected
from the free wall of the right or left ventricle (LV) [6].
Although available data indicate that complication rate is
not high, this procedure is associated with potentially
serious complications. It stands to reason that lowering
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the incidence of critical complications is a major concern
in performing EMB.
The aim of the present study was to evaluate clinical
and histopathological findings of EMBs. We also assessed
safety of EMB through the description and quantification
of the procedure related complications.
Methods
All consecutive patients who underwent EMB between July
2008 and May 2015 at the Department of Cardiology,
Poznan, Poland were included in this retrospective analysis.
Bioethics Committee at the Poznan University of Medical
Sciences approved the study. Authors obtained written con-
sent from all patients participating in the study.
Biopsies were performed according to current guidelines
as a tool for the diagnostic evaluation of suspected myocar-
ditis, unclear heart failure, unexplained cardiomyopathy,
assumed infiltrative and storage disease or as a part of rou-
tine allograft rejection monitoring and clinically suspected
rejection diagnosis in heart transplant recipients [2].
In patients who underwent heart transplantation (HTx),
EMB procedures were made in accordance with a current
protocol: a week after HTx, every 2 weeks for the next
8 weeks, once for the next 4 weeks, once for the next
6 weeks, then every 3 months for the next two years, and
afterwards every 12 months for the next years [7]. The two
nondiagnostic myocardial specimens were excluded from
the study.
Endomyocardial biopsy procedure
All EMB procedures were performed via the right femoral
vein access under fluoroscopic guidance. In some cases
additionally 2D-echocardiography support was used. A 7F
long, curved sheath (96 cm, Cordis) was placed in the right
ventricle (RV) and the bioptome was used to collect speci-
mens. 6 ± 2 myocardial tissue samples, 1–2 mm in the
diameter were harvested from the apical segment of the
right side of IVS (Fig. 1). All EMB procedures were limited
to the two experienced operators. Harvested myocardial
tissue specimens were fixed in 10% buffered formalin and
then sent for further histopathological evaluation.
Additional samples were collected on 0.9% saline or
immediately frozen in optimum cutting temperature com-
pound with watersoluble glycols cooled in liquid nitrogen
and stored at −80 °C. For transmission electron microscopy,
EMB samples were fixed in 2% glutaraldehyde in 0.1 mol/L
phosphate buffer (pH 7.3).
In addition to continuous electrocardiographic monitor-
ing, right atrial pressure and right ventricular (RV) pres-
sures were recorded before as well as promptly after
sampling to detect potentially impending pericardial tam-
ponade. Moreover, a 12-lead electrocardiogram (ECG),
ECG monitoring, transthoracic echocardiography before
and immediately after as well as 12 h after EMB procedures
were assessed to obtain a detailed evaluation of the inci-
dence of conduction abnormalities, arrhythmias, pericardial
effusions and worsening valve insufficiency.
Histopathological assessment
Histological evaluation was performed by one experienced
pathologist. The diagnosis of allograft rejection was per-
formed according to the revised International Society for
Heart and Lung Transplantation (ISHLT) classification [8].
In suspicion of myocarditis, the diagnosis was confirmed
based on the histopathological Dallas criteria, immuno-
chemistry and viral genome analysis results [9]. The diag-
nosis of specific type of cardiomyopathy was made in
accordance with the recommendations of American Heart
Association/European Society of Cardiology [10, 11].
Furthermore, the presence of well-formed granulomas with
negative stains for microorganisms were the criteria used
for the confirmation of sarcoidosis. The identification of
infiltrative amyloidosis disease was reached by use Congo
red stains and electron microscopy. Cardiac toxicity was
diagnosed in the presence of loss of myofibrils, increased
fibrosis and vacuolization of the cytoplasm.
Complications classification
Complications resulting from the procedure were classi-
fied as major or minor according to the risk of death.
Definition and assessment of major and minor EMB
complications were in accordance with previous studies
[12, 13]. Major complications were defined as: death,
pericardial tamponade, hemo- and pneumopericardium,
Fig. 1 Endomyocardial biopsy (EMB) of right ventricle (RV) “step-by-step”: a Confirmation of the position of 7F curved sheath inside RV with the
use of pig-tail catheter and small amount contrast injection. b Biopsy forceps opened and c closed. 5–10 samples of myocardium are usually
taken during the procedure
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permanent atrioventricular block requiring pacemaker
implantation, myocardial infarction, transient cerebral is-
chemic attack and stroke, severe tricuspid valve damage,
while minor complications included transient chest pain,
access site hematomas, transient arrhythmias, transient
hypotension, and small pericardial effusions.
Statistical Analysis
Continuous variables were expressed as mean ± standard
deviation (SD). Categorical variables were presented as
absolute values and percentages. Statistical analyses were
performed using Microsoft Excel Office 2011 software
(Microsoft Corporation, Redmond, Wash).
Results
A total of 315 EMB procedures were performed among
73 patients. The majority of recorded patients were men
(57 of 73, 78.1%). The mean age of patients was 47.6 ±
12.1 years (range: 18–68 years). The detailed baseline
patient characteristics are present in Table 1.
Among all the 315 biopsies, 86.67% were EMB proce-
dures performed in patients after HTx. Myocarditis was the
second most frequently diagnosed condition with the inci-
dence of 3.81%. It was followed by dilated cardiomyopathy
that reached 2.54%. Amyloidosis was diagnosed with a rela-
tively high incidence in 1.9% of EMB procedures. Drug-
induced cardiomyopathy, cardiac tumor and peripartum
cardiomyopathy were the rarest identified entities, with the
incidence of 0.32%. Table 2 lists the detailed frequency of
each diagnosed cardiac disorder.
Among the 273 EMB procedures performed in 32 HTx
recipients, moderate rejection (grade 2a) was detected in 7
biopsy samples (2.56%), while mild (grade 1a) was
observed in 56 samples (20.5%). 210 samples (76.9%) did
no show evidence of cellular allograft rejection. Moreover,
all moderate rejections were detected during first
24 months after HTx, and 3 of 4 moderate rejections oc-
curred in the first 6 months after HTx.
The overall complications rate was 1.9% (6 of 315 proce-
dures). Major complications included 2 cases (0.64%) of
perforation requiring surgical intervention. There was no
death associated with the EMB procedure. Minor complica-
tions included one case of pericardial effusion, 2 cases of
local hematoma and one case of right coronary artery-right
ventricular fistula in HTx recipient (Fig. 2) (See Table 3).
Table 4 presents the detailed characteristics of patients with
EMB complications. The coronary artery fistula was asymp-
tomatic and small in size. It was diagnosed in the TTE and
annual coronary arteriography. There was no difference in
the complication rate between the two operators, each of
them performed one EMB procedure complicated by
tamponade.
Discussion
Since the introduction of catheter-based myocardial biopsy
by Sakakibara and Konno in 1962, EMB has been consid-
ered a valuable tool for evaluation of cardiac tissue for
cardiomyopathy, myocarditis, unexplained arrhythmia,
cardiac tumor, cardiac involvement of systemic disease and
cardiac allograft rejection. Available data indicate that EMB
is generally safe procedure, with relatively low complications
rate. Possible major complications associated with EMB
procedures include: pericardial effusion, pericardial tam-
ponade requiring pericardiocentesis, hemo- and pneumo-
thorax, myocardial infarction, transient ischemic attack,
stroke, permament complete atrioventricular block, severe
tricuspid regurgitation or death. As minor complications are
reported: small pericardial effusions, transient chest pain,
transient arrhythmias, hypotension, local nerve paresis, local
hematoma, and femoral arterial-venous fistula [6].
The present study confirmed the safety of EMB. The
cumulative complication rate was 1.9%. In the literature
EMB- related complications rate varies from 0.71% to
9.2% [14, 15]. In previous studies major complications
was reported in less than 1.5% of performed procedures,
while minor complications ranged between 1.0% and
7.9% [15, 16]. See Table 5.
In our study the risk of major complications was low -
0.64%. The only serious complication among our pa-
tients was iatrogenic cardiac perforation with subsequent
tamponade requiring surgical intervention. Pericardial
tamponade occurred in 2 patients (0.64% of all EMB
procedures), in one patient with myocarditis and in an-
other one with tumor in the right ventricular outflow
tract. One patient developed asymptomatic pericardial
effusion not progressed to cardiac tamponade.
One of patient after HTx developed right coronary ar-
tery to right ventricle fistula. It was reported that re-
peated EMBs in heart transplant recipients are directly
related to the incidence coronary arteries fistulas [17].
Nevertheless, there was no association between the
number of performed EMBs in HTX recipients with and
without coronary artery fistula [18]. The great majority
of coronary artery fistulas are benign condition. In the
literature, there is described the relatively high rate of
spontaneous closure of fistula, what favors a conserva-
tive “watchful waiting “approach [14–18]. Due to a small
size and asymptomatic course of the right coronary ar-
tery to right ventricle fistula in our patient conservative
approach was adopted.
All of the EMB procedures were performed by two
highly experienced interventional cardiologists. This find-
ings support results of recent studies that the incidence of
major complication was lower when EMB was performed
by experienced operators [12]. Isogai et al. found that
higher hospital volume was associated with lower rates of
major complications after EMB. Pericardiocentesis was
Sławek et al. BMC Cardiovascular Disorders  (2016) 16:222 Page 3 of 8
needed in 0.4% in the low-volume hospitals, in 0.2% in
medium-volume hospitals and in 0.1% in high-volume
hospitals, respectively (p = 0.019). The rates of temporary
pacing also were lower in the high-volume hospitals
(0.2%) in comparison to the low-volume (1.0%) and
medium-volume hospitals (0.7%) (p < 0.001) [19].
Table 1 Baseline patients characteristics






Age (years) 47.6 ± 12.1 48.91 ± 11.24 40.02 ± 14.53
Sex
Females 16 9 7
Males 57 23 32
BMI (kg/m2) 24.37 ± 4.11 24.31 ± 3.99 24.05 ± 5.43
NYHA Class
I, II, 35 31 4




Myocardial infarction 0 0 0
Hypertension 11 11 0
















Renal failure 14 9 5
GFR (ml/min/m2) 71.66 ± 23.48 53.2 ± 23.16 72.83 ± 12.17
Blood pressure (mmHg)
Systolic 127.58 ± 15.29 129.89 ± 33.3 99.00 ± 12.04
Diastolic 81.38 ± 11.23 82.95 ± 9.54 81.38 ± 11.23
Electrocardiogram












95.26 ± 13.48 95.98 ± 13.37 84.60 ± 12.18
PQ-interval (s) 0.147 ± 0.043 0.160 ± 0.06 0.14 ± 0.06
QRS-width (s) 0.119 ± 0.022 0.120 ± 0.06 0.18 ± 0.018




Negative T-wave 5 2 3
Cardiac Biomarkers
Creatine kinase (U/L) 85.78 ± 82.17 38.26 ± 75.68 187.00 ± 192.85
Creatine kinase-
MB (U/L)
21.44 ± 8.64 21.27 ± 8.86 16.2 ± 15.81
Troponin I (ng/mL) 0.37 ± 1.67 0.23 ± 0.97 4.51 ± 2.75
Brain natriuretic
peptide (pg/mL)
312.08 ± 365.13 261.13 ± 284.35 948.02 ± 641.85
Table 1 Baseline patients characteristics (Continued)
Laboratory results on admission
C-reactive protein
(mg/L)




7.8 ± 1.2 7.61 ± 1.04 10.35 ± 0.67
White blood cell
count (1 × 109/L)
6.47 ± 3.44 6.23 ± 3.19 10.23 ± 5.41
Platelets count
(1 × 109/L)
107.78 ± 57.27 205.13 ± 56.97 215.83 ± 55.42
Echocardiography




45.92 ± 14.65 44.41 ± 4.58 68.33 ± 10.04
Interventricular
septum (mm)
11.9 ± 2.14 12.00 ± 2.07 9.91 ± 2.20








32.39 ± 8.72 32.27 ± 9.00 33.25 ± 4.71
Pericardial effusion
< 4 mm 6 4 2
> 4 mm 0 0 0
Tricuspid valve dysfunction
Mild 5 5 2
Moderate 3 1 6
Severe 0 0 2
Cardiac catheterization
Right atrial pressure (mmHg)
Systolic 14.00 ± 7.18 12.00 ± 6.00 16.00 ± 9.00
Diastolic 8.00 ± 5.30 6.00 ± 3.50 10.00 ± 7.00
Mean 11 ± 6.14 8.00 ± 2.70 14.00 ± 8.00
Right ventricular pressure (mmHg)
Systolic 39.2 ± 17.73 27.00 ± 6.00 51.00 ± 18.4
Diastolic 7.33 ± 8.55 6.00 ± 4.00 8.00 ± 9.00
End diastolic 10 ± 6.83 4.00 ± 5.50 15.00 ± 5.00
Pulmonary Artery Pressure (mmHg)
Systolic 31.00 ± 11.64 24.00 ± 7.00 39.00 ± 11.00
Diastolic 16.33 ± 9.91 12.00 ± 5.00 20.00 ± 13.00
Mean 19.30 ± 13.70 15 ± 7.00 30.00 ± 16.50
Continuous variables are presented as mean ± SD. Categorical variables are
presented as absolute values (n=). NYHA New York Heart Association
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It is also known that the frequency of complications,
especially minor is associated with operative technique,
heart disease and quality of patients monitoring. In this
work all biopsies were performed via femoral vein access
that allows avoiding the risk of pneumothorax or hemo-
thorax related to internal jugular venous access. How-
ever, femoral venous access is associated with an
increased risk of a deep vein thrombosis and pulmonary
embolism because of the obligate immobilization and
application of longer sheaths. Recently, Imanura et al.
described that internal jugular access was associated
with lower operation and radiation exposure times, and
lower radiation exposure dose and contrast usage com-
pared with the femoral approach [20]. Nevertheless, the
full interpretation of these results is limited by the retro-
spective nature of the study, lack of the randomization,
biased patients allotments to applied technique.
What is more, Imanura et al. reported that internal jugu-
lar vein approach had less overall complications rate than
the femoral vein approach 2.7% versus 10.0% (p = 0.011).
All complications were transient, but only internal jugular
vein approach was complicated by transient neurologic
events in 0.9% (3 of 329 EMBs). Moreover, only femoral
vein access was complicated by nonsustained ventricular
tachycardia 4% (2 of 50 EMBs) and transient bundle
branch block 4% (2 of 50 EMBs), whereas internal jugular
vein access was complicated by atrial tachyarrhythmia
0.9% (3 of 329 EMBs) [20]. In the study of Strecker et al.
major complications after EMB performed through the
right internal jugular vein occured in 1.0% of EMBs (19 of
1896 EMBs). Twelve patients developed moderate or severe
tricuspid regurgitation with increased pulmonary artery sys-
tolic pressure and six of these patients received mechanical
or biological tricuspid valve prosthesis. In six other patients
echocardiography showed pericardial effusions around the
right and left ventricle with signs of tamponade, these
patients underwent pericardiocentesis on the same day.
The another one patient developed supraventricular tachy-
cardia during the biopsy, but remained asymptomatic [21].
Although small discrepancies, the results these studies indi-
cate that the incidence of major complication was similar
when using the femoral vein or jugular vein access.
Interestingly, last findings revealed that left ventricular
endomyocardial biopsy (LVEMB) is as safe as right ven-
tricular EMB. Chimenti et al. reported low incidence of
major complication after LVEMB and comparable to
after RVEMB, 0.33% and 0.45%, respectively. Moreover,
the risk of perforation was lower in LVEMB in compari-
son to RVEMB, likely due to the thinner walls of the RV,
which are easier to perforate by the bioptome. In all







Inflammatory cardiomyopathy 5 1.59
Dilated cardiomyopathy 8 2.54
Hypertrophic cardiomyopathy 4 1.27
Peripartum cardiomyopathy 1 0.32
Drug-induced cardiomyopathy 1 0.32
Cardiac toxicity 2 0.64
Cardiac tumor 1 0.32
Sarcoidosis 2 0.64
Amyloidosis 6 1.9
Heart transplant state 273 86.67





All complications 6 1.9
Major complications 2 0.64
Perforation with pericardial tamponade 2 0.64
Minor complications 4 1.28
Pericardial effusion 1 0.32
Access site hematoma 2 0.64
Right coronary artery-right ventricular fistula 1 0.32
Without complications 309 98.1
Fig. 2 Right coronary artery to right ventricle fistula after endomyocardial biopsy in a patient after heart transplantation. a Angiography of right
coronary artery in a patient 3 months after HTX – no signs of fistula. b Coronary angiography directly following EMB 12 months after HTX. Well
visible fistula to right ventricle. Left anterior oblique projection. c Right anterior oblique (RAO) projection
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NYHA New York Heart Association, RCA right coronary artery, RV right ventricle
Table 5 Risk of endomyocardial biopsy (EMB) complications reported in previous studies
Author (year) Number of biopsies Overall complications rate (%) Major complications rate Minor complications rate Reference
Deckers (1992) 546 6 1.2a 4.8a [24]
Hiramitasu (1998) 19 964 0.7 [25]
Felker (1999) 323 0.32 [26]
Holzmann (2008) 3048 1.25a 0.1a 1.15a [12]
Yilmaz (2010) 622 (LVEMB) 3.5 (LVEMB) 0.6 (LVEMB) 2.9 (LVEMB) [13]
490 (RVEMB) 5.9 (RV EMB) 0.8 (RVEMB) 5.1 (RVEMB)
Huang (2010) 439 1.61 0.0 1.61 [27]
Saraiva (2011) 2217 0.71 - - [14]
Fiorelli (2012) 5347 6.2 0.3 5.9 [28]
Bennet (2013) 851 1.9 0.9 1.0 [16]
Jang (2013) 228 9.2 1.3 7.9 [15]
Chimenti (2013) 3549 (LVEMB) 2.33 (LVEMB) 0.33 (LVEMB) 2.0 (LVEMB) [22]
3068 (RVEMB) 1.8 (RVEMB) 0.45 (RVEMB) 1.35 (LVEMB)
Strecker (2013) 1896 1.0 [21]
Isogai (2015) 9508 0.98 [19]
Schulz (2015))~ 37 2.7 0 2.7 [1]
Schäufele (2015)~ 41 0 0 0 [23]
avalues calculated on the basis of the manuscript data; LVEMB- left ventricle endomyocardial biopsy; RVEMB-right ventricle endomyocardial biopsy; ~ -
transradial approach
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cases of LV perforation, authors found significant dilata-
tion [13]. Among 755 patients with myocarditis or di-
lated cardiomyopathy the major complications after
LVEMB occurred 0.64%, while after RVEMB in 0.82%
[22]. Recently, Schulz et al. demonstrated the feasibility
and safety of the transradial approach for LVEMB. EMB
procedures were conducted in 37 patients. The overall
complication rate was 2.7%, only one patient developed
ventricular fibrillation which was terminated by external
defibrillation [1]. Schäufele et al. included 42 patients
and performed 41 transradial biopsy procedures. In one
case they crossed over to femoral approach because of
irreversible spasm of the right radial artery after admin-
istration of local anesthesia. They did not describe any
complications after EMB, and the quality of obtained
samples was good [23]. The application of transradial
access may be reasonable in situations when simultan-
eous coronary angioplasty is desirable.
Study limitations
The present study has several limitations. First, the present
study was performed at a single center in a retrospective
manner. Second, the approach point was not randomized,
and selection bias existed in the present study. Third, we
evaluated only the safety of EMB performed via the femoral
vein access and we were not able to assess the complication
rate associated with different approaches. Fourth, we ac-
knowledge this study was limited by small numbers of
patients, which make the results difficult to extrapolate to a
larger population. The number of heart transplant patients
was very small in this study, mainly due to severe shortage
of donors in Poland and rarely performed heart transplants.
Although the major complication rate in our study was
similar to previous larger studies, it is of limited accuracy
due to insufficient number of EMB procedures. Finally,
another issue relates that we included all patients who
underwent EMBs procedure, not only these with stable
hemodynamics. Therefore, the results obtained in these
patients may not be simply compared with other studies
assesing only hemodynamically stable patients, in which
EMB may have a lower complication rate.
Conclusions
In conclusion, EMB is a safe procedure with low risk of
serious complications and high effectiveness for the
evaluation of unexplained left ventricle dysfunction and
monitoring allograft rejection after HTx.
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